Anaptysbio (ANAB) Short-term Investments (2017 - 2026)

Anaptysbio has reported Short-term Investments for 10 years, with the latest figure at $38.0 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 84.26% year-over-year to $38.0 million; the trailing twelve-month figure through Mar 2026 stood at $38.0 million (down 84.26% YoY), and the FY2025 full-year result was $73.4 million, down 72.0% from the prior year.
• Short-term Investments for Q1 2026 stood at $38.0 million, down from $73.4 million in the prior quarter.
• The five-year high for Short-term Investments was $394.3 million in Q2 2023, with the low at $38.0 million in Q1 2026.
• Historically, Short-term Investments has averaged $278.3 million across 5 years, with a median of $301.0 million in 2024.
• Annual changes were most pronounced in 2022 — Short-term Investments jumped 617316.67% — and 2026, when it slumped 84.26%.
• Anaptysbio's Short-term Investments stood at $369.9 million in 2022, then fell by 4.05% to $354.9 million in 2023, then dropped by 26.1% to $262.3 million in 2024, then plunged by 72.0% to $73.4 million in 2025, then tumbled by 48.28% to $38.0 million in 2026.
• The last three Short-term Investments figures came in at $38.0 million (Q1 2026), $73.4 million (Q4 2025), and $139.1 million (Q3 2025), per Business Quant data.